Very intriguing stuff. I find it interesting that this is a phase 2a trial with limited enrollment and no control arm (Placebo) to compare response rate. The best control they have is what the doctor stated: "It is uncommon for patients with moderate-to-severe plaque psoriasis to spontaneously improve without treatment." While that statement may be very accurate, it is at best a soft metric and not a data driven, scientifically tested piece of evidence for efficacy.

That all being said; I am not good at interpreting the data, but the results appear promising. Best of luck to them, and even though P is for mild/moderate and not necessarily in competition with Galectin, I am glad to see they are so much further behind in their phase 2 trials. Plus P has the overwhelming advantage over them, and most other psoriasis drugs on the market, by being orally administered. I still continue to believe that quality alone makes P many, many times more valuable than the topical or intravenous drugs on the market. Hell, P could perform worse than other drugs of those types and I am confident there will be a strong market for it because humans will always try the easy, convenient, and less risky solution first before they move on to the other more difficult ones.